The latest update is out from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ).
Hemogenyx Pharmaceuticals has successfully treated a second patient in its Phase I clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia in adults. This milestone signifies progress in the clinical development of HG-CT-1, with the potential to transform treatment options for patients with limited alternatives and generate long-term value for shareholders. The trial aims to establish HG-CT-1 as a significant asset in hematologic malignancies, with future plans for pediatric trials to address unmet medical needs in AML.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals plc is a publicly traded biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging distinct product candidates and platform technologies for novel product development.
YTD Price Performance: -55.12%
Average Trading Volume: 36,948
Technical Sentiment Signal: Buy
Current Market Cap: £7.44M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “Be the Leader You’ve Been Complaining For!” Paramount Stock (NASDAQ:PARA) Dips as Paramount Pulls Out of Politics
- Don’t “Get Rid of All Your Engine Designers”: Ford Stock (NYSE:F) Dips as it Brings Back a Big Name in Internal Combustion
- “Advanced Silicon Wafer Tests” Start; Intel Stock (NASDAQ:INTC) Slips